KUALA LUMPUR, May 16 (Bernama) -- Invivoscribe Technologies Inc released the LymphoTrack Dx TRB Assay, complete suite of CE-marked next-generation sequencing (NGS) clonality assays for the Illumina MiSeq Platform for in vitro diagnostic (IVD) use.
"NGS-based LymphoTrack Dx Assays benefit patients by guiding precision treatments and enabling exceptionally sensitive monitoring for disease reoccurrence, " said chief scientific officer and chief executive officer Invivoscribe, Dr. Jeffrey Miller.
The LymphoTrack Dx TRB assay identifies clonal rearrangement sequences which accompanied with bioinformatics software to provide a clear summary of the frequency distribution as the clonal sequences able to monitor minimal residual disease in longitudinal studies and the effectiveness of therapies aimed towards eradication.
The CE-marked clonality kits allow single step PCR library generation, with bioinformatics software to run on standard Windows platforms within customer laboratories and allow for comprehensive multiplex testing of any combination of samples and LymphoTrack Dx assays.
Each kit includes user-friendly LymphoTrack Dx MiSeq software that automates the sorting and tracking of each sample and target, interprets sequence data, and generates detailed reports, a statement said.
Invivoscribe also offers a complete suite of CE-marked NGS clonality assays designed to assess clonality for both diagnostic and tracking purposes. The LymphoTrack Dx TRB Assay for the ThermoFisher Scientific Ion PGM and Ion S5 instruments will be released later this year.
Invivoscribe is a privately held biotechnology company dedicated to improving the quality of healthcare worldwide by providing high quality, standardized reagents, tests and bioinformatics tools. More information at www.invivoscribe.com.
--BERNAMA
No comments:
Post a Comment